Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous XXXX .

@entity1 @entity66 @entity41 @entity242 @entity5 @entity4969 @entity900 @entity2969 @entity420
BACKGROUND: After chemotherapy for nonseminomatous @entity2969 (NSTGCT), residual masses or recurrent disease may contain a non-germ cell malignancy (NGCM). METHODS: Over 20 years, 369 @entity1 with disseminated NSTGCT were treated with @entity900 -based polychemotherapy at the University Medical Center Groningen. @entity41 masses were resected in 244 @entity1 and recurrent @entity5 masses in 37 @entity1 . Histology was reviewed, focusing on the presence of NGCM. RESULTS: Nine @entity1 developed an NGCM. Four @entity1 had an NGCM in the resected @entity41 mass after chemotherapy: three @entity1 had a @entity242 , and one @entity1 had both a @entity242 and an @entity420 . Five @entity1 developed a late recurrence with an NGCM after 39, 40, 72, 72, and 84 months. One @entity1 had a primitive @entity4969 , one had a @entity242 , and three had an @entity420 in the resected recurrent @entity5 mass. A complete surgical resection was achieved in five (56%) of the nine @entity1 . After a median follow-up of 48 months (range, 3-271 months), five @entity1 had no evidence of disease (56%), three @entity1 were @entity66 (33%), and one @entity1 was alive with disease (11%). CONCLUSIONS: @entity242 , @entity420 , or both in residual or recurrent @entity5 masses after combined-modality NSTGCT treatment are rare. Complete surgical resection of the @entity5 mass is the only curative treatment option.
